Abstracts tagged "Cohort Study"

Abstract Number: 0497 • ACR Convergence 2023
Effects and Tolerability of Low to Moderate Biomechanical Stress During Leisure Sport Activity in Patients with Psoriasis and Psoriatic Arthritis
Filippo Fagni¹, Melek Yalcin Mutlu¹, Ioanna Minopoulou¹, Selahattin Alp Temiz², Manuel Krieter³, Georg Schett⁴, Arnd Kleyer⁵, David Simon¹ and Axel Hueber⁶, ¹Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology / Deutsches Zentrum Immuntherapie, Erlangen, Germany, ²University Hospital Erlangen and Friedrich-Alexander University (FAU) Erlangen-Nürnberg, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, ³Department of Dermatology, Klinikum Nürnberg, Paracelsus Medical University, Nürnberg, Germany, ⁴Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁵University Hospital Erlangen, Erlangen, Germany, ⁶Division of Rheumatology, Klinikum Nürnberg, Paracelsus Medical University / Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Nürnberg, Germany
Background/Purpose: International guidelines advise physical activity as complementary measure to drug treatment for patients with RA. However, this can hardly be extrapolated for PsA, for which…
Abstract Number: 0982 • ACR Convergence 2023
Systemic Autoimmune Rheumatic Diseases (SARD) in the Agricultural Health Study Cohort: Rates of Rheumatoid Arthritis (RA) and Other SARD Among Medicare-linked Participants
Christine Parks¹, Karen Costenbader², Laura Beane Freeman³, Jonathan Hofmann³ and Dale Sandler⁴, ¹Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, ⁴Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Durham, NC
Background/Purpose: Some systemic autoimmune rheumatic diseases (SARD), such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), have been associated with farming, specific pesticides, and…
Abstract Number: 1530 • ACR Convergence 2023
Outcomes in Patients with Systemic Sclerosis Following Lung Transplantation: An Italian Multicentre Experience
Claudia Iannone¹, Maria Rosa Pellico¹, Letizia Corinna Corinna Morlacchi², Valeria Rossetti², Marco Vicenzi², Paolo Airò³, Marta Saracco⁴, Annamaria iagnocco⁴, Lorenzo Beretta⁵, Adriana Severino⁵, Eleonora Zaccara⁶, paola Faggioli⁶, Fabio Cacciapaglia⁷, Stefano Stano⁸, Silvia Cavalli⁹, Antonina Minniti⁹, giorgia Trignani⁹, francesco Blasi⁵, Roberto F. Caporali¹⁰ and Nicoletta Del Papa¹¹, ¹ASST Gaetano Pini CTO, Milan, Italy, ²Policlinico di Milano, Milan, Italy, ³Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, ⁴AO Mauriziano di Torino, Torino, Italy, ⁵Policlinico di Milano, Milano, Italy, ⁶Legnano-ASST-Ovest Milanese, Legnano, Italy, ⁷Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari, Bari, Italy, ⁸Policlinico di Bari, Bari, Italy, ⁹ASST Gaetano Pini CTO, Milano, Italy, ¹⁰Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy, ¹¹Scleroderma Clinic, Dipartimento di Reumatologia, ASST Gaetano Pini CTO, Milano, Italy
Background/Purpose: Lung transplantation (LT) is gaining ground in managing advanced ILD in SSc patients. However, concerns remain among surgeons due to SSc's complexity, multiorgan involvement…
Abstract Number: 2302 • ACR Convergence 2023
Persistently Active Disease in Adult Patients with Childhood Onset Systemic Lupus Erythematosus
Rachel Koelmeyer¹, Kate gregory¹, Rangi Kandane-Rathnayake², Fiona Goldblatt³, Sean O’Neill⁴, Maureen Rischmueller⁵, Mandana Nikpour⁶, Geraldine Hassett⁷, Pravin Hissaria⁸, Darakanathan Ranganathan⁹, Claire Barrett¹⁰, Ashleigh Hennessey⁹, Ted Tsai¹¹, Peter Gowdie¹², Eric Morand¹³ and Alberta Hoi¹⁴, ¹Monash University, Clayton, Australia, ²Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Clayton, Australia, ³Royal Adelaide Hospital and Flinders Medical Centre, Adelaide, Australia, ⁴Department of Medicine, University of New South Wales, Kensington, Australia, ⁵The Queen Elizabeth Hospital and Basil Hetzel Institute; Adelaide Medical School, University of Adelaide, Adelaide, Australia, ⁶The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia, ⁷Liverpool Hospital, Liverpool, Australia, ⁸Royal Adelaide Hospital, Adelaide, Australia, ⁹Royal Brisbane and Women's Hospital, Herston, Australia, ¹⁰Redcliffe Hospital, Redcliffe, Australia, ¹¹Canberra Hospital, Garran, Australia, ¹²Monash Health, Clayton, Australia, ¹³Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ¹⁴Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia
Background/Purpose: Previous studies in childhood-onset systemic lupus erythematosus (cSLE) have suggested that cSLE patients have more severe disease, compared to those with adult-onset disease (aSLE).…
Abstract Number: 0154 • ACR Convergence 2023
Impact of Social Determinants of Health (SDoH) on Survey Response Times Among Lupus Patients
Daniel Bao¹, Charmayne Dunlop-Thomas², Cristina Drenkard² and S. Sam Lim², ¹Johns Creek High School, Johns Creek, GA, ²Emory University, Atlanta, GA
Background/Purpose: Social determinants of health (SDoH) significantly impact outcomes of Systemic lupus erythematosus (SLE) patients. However, little is known about the influence of SDoH on…
Abstract Number: 0542 • ACR Convergence 2023
Two-Year Treatment Adherence and Clinical Response to Secukinumab Compared to TNF Inhibitors in Axial and Peripheral Spondyloarthritis Patients: A Single-Center Prospective Observational Study
Irini Flouri¹, Argyro Repa², Nestor Avgoustidis², Sofia Pitsigavdaki³, Katerina Pateromichelaki², Maria Terizaki², George Bertsias⁴ and Prodromos Sidiropoulos⁴, ¹University of Crete Medical School, Heraklion, Greece, ²Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Heraklion, Greece, ³Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Crete, Greece, ⁴Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Greece; Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas (FORTH), Heraklion, Greece
Background/Purpose: Anti-IL17 agent secukinumab (SEC) has been proven effective and is widely used in the treatment of spondyloarthritis (SpA) patients alternatively to tumor necrosis factor…
Abstract Number: 1072 • ACR Convergence 2023
Increase in Major Osteoporotic Fractures After Therapy with Immune Checkpoint Inhibitors
Maria Suarez-Almazor¹, Carrie Ye², Bo Zhao³, Juan Ruiz³, Hui Zhao³, Noha Abdel-Wahab⁴ and William Leslie⁵, ¹MD Anderson Cancer Center, Houston, TX, ²University of Alberta, Edmonton, AB, Canada, ³The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴University of Texas MD Anderson Cancer Center, Houston, TX, ⁵University of Manitoba, Internal Medicine, Winnipeg, MB, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of cancer. Despite their efficacy on tumor outcomes they can cause severe and sometimes long-standing immune-related…
Abstract Number: 1543 • ACR Convergence 2023
The Association of Frailty with Outcomes in Patients with Vasculitis
Sebastian Sattui¹, John Stadler², Renee Borchin³, Cristina Burroughs³, Christine Yeung⁴, Peter Merkel⁴ and Robert Spiera⁵, ¹University of Pittsburgh, Pittsburgh, PA, ²Vasculitis Foundation, Kansas City, MO, ³University of South Florida, Tampa, FL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Hosptial for Special Surgery, New York, NY
Background/Purpose: Frailty is associated with poor health outcomes including increased risk of hospitalizations, infections, and fractures. In the baseline survey of the VascStrong study, we…
Abstract Number: 2304 • ACR Convergence 2023
Disparity in Healthcare in Systemic Lupus Erythematosus: A Single-Center Study
Joshua Reed, Anam Nazir, Khalid Alghamdi and Catherine Ivory, The Ottawa Hospital Research Institute, Ottawa, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is variable in clinical presentation and has fluctuating disease severity. Health outcomes in SLE have been linked to both genetic…
Abstract Number: 0188 • ACR Convergence 2023
Association Between Area Deprivation Index and Organ Damage Accumulation in a Statewide Incident Lupus Cohort
Jonathan Katz¹, Bryn Sutherland², Ang Yu³, Jenna Cormier², Yiran Jiang², David Gazeley⁴, Felix Elwert³ and Christie M. Bartels⁵, ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Medical College of Wisconsin, Milwaukee, WI, ³Department of Sociology, University of Wisconsin, Madison, WI, ⁴Medical College of Wisconsin, Wauwatosa, WI, ⁵University of Wisconsin, School of Medicine and Public Health, Madison, WI
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a heterogenous systemic autoinflammatory disease that disproportionately effects young women and minoritized populations. Disparities are multifactorial with genetic, hormonal,…
Abstract Number: 0561 • ACR Convergence 2023
Frequency of Anti-Ro Antibodies in Systemic Lupus Erythematosus Patients: Insights from Multicenter and National Registry
Lucia Margarita Mendoza Martinez¹, Joan Manuel Dapeña¹, Juan Manuel Bande¹, Maria Alejandra Medina¹, Silvia Papasidero¹, José caracciolo¹, Rosana Quintana², Lucila Garcia², Carla Andrea Gobbi², Sandy Sapag Durán², Alberto Spindler², Analia Patricia Alvarez², Cecilia Pisoni², Catalina Gomez², Raúl Hector Paniego², María Julia Santa cruz², Luciana Gonzalez Lucero², Rodrigo Aguila Maldonado², Sergio Gordon², Julia Romero², Gretel Rausch², Alberto Allievi², Alberto Omar Orden², johana zacariaz hereter³, Roberto Baéz², Andrea Vanesa González², Juan Manuel Vandale², Mario Alberto Goñi², Victor Caputo⁴, María Silvia Larroudé², Graciela Gómez², Josefina Marin², Victoria Collado², Gazzoni María Victoria², Marcos David Zelaya², Mónica Sacnún², Romina Rojas Tessel², Maira Alejandra Arias Saavedra², Maximiliano Machado Escobar², Pablo Astesana², Ursula Vanesa Paris², Bernando A. Pons-Estel² and Mercedes García⁵, ¹Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ²Study Group of the Argentine Society of Rheumatology for Systemic Lupus Erythematosus, Buenos Aires, Argentina, ³Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Hospital Militar Central, Buenos Aires, Argentina, ⁵Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina
Background/Purpose: Anti-Ro antibodies can be detected in 40% of patients with systemic lupus erythematosus (SLE) and have been associated with various clinical manifestations of the…
Abstract Number: 1075 • ACR Convergence 2023
Impact of Immunosuppression on the Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Rheumatic Autoimmune Disease: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
Lourdes Gonzalez Arreola¹, Carrie Ye², Marie Hudson³, Janet Roberts⁴, Janet Pope⁵, Thomas Appleton⁵, Sabrina Hoa⁶, Aurore Fifi-Mah⁷, Nancy Maltez⁸, Alexandra Saltman⁹, Megan Himmel⁹, Ines Colmegna¹⁰, Alexandra Ladouceur¹¹, Anthony Obrzut¹, Jeremiah Tan¹², David Moon², Tatiana Nevskaya⁵, Emma Schmidt¹³, Lindsay Cho⁴, Nader Toban¹⁴ and Shahin Jamal¹⁵, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²University of Alberta, Edmonton, AB, Canada, ³McGill University, Montréal, QC, Canada, ⁴Dalhousie University, Halifax, NS, Canada, ⁵University of Western Ontario, London, ON, Canada, ⁶University of Montreal, Brossard, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸The Ottawa Hospital, Ottawa, ON, Canada, ⁹University of Toronto, Toronto, ON, Canada, ¹⁰The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹¹Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, ¹²Arthritis Research Canada, Vancouver, Canada, Vancouver, BC, Canada, ¹³University of British Columbia, Vancouver, BC, Canada, ¹⁴Centre Hospitalier de l'Université de Montréal, Dollard-des-Ormeaux, QC, Canada, ¹⁵Vancouver Coastal Health, Vancouver, BC, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) have changed the landscape of treatment for many cancers. However, most cancer clinical trials for ICI excluded patients with pre-existing…
Abstract Number: 1632 • ACR Convergence 2023
Incident Malignancies in Patients with Rheumatoid Arthritis in Daily Rheumatological Care
Martin Schaefer¹, Yvette Meissner¹, Bernhard Manger², Sylvia Berger³, Karin Rockwitz⁴, Anne Regierer⁵ and Anja Strangfeld¹, ¹German Rheumatism Research Center, Berlin, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Rheumatologist, Naunhof, Germany, ⁴Rheumatologist, Goslar, Germany, ⁵Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany
Background/Purpose: In 2021, the European and US-American regulatory agencies EMA and FDA issued warnings about malignancy risk associated with the Janus kinase inhibitor (JAKi) tofacitinib…
Abstract Number: 2308 • ACR Convergence 2023
The Association Between Poverty and SLE Disease Burden: Experiences from a Saint Lucian Cohort
Amanda King¹, Catherine Brown², Cleopatra Altenor¹, Timothy Niewold³ and Ashira Blazer³, ¹Bay Medical Centre, Castries, Saint Lucia, ²The University of the West Indies, Bridgetown, Barbados, ³Hospital for Special Surgery, New York, NY
Background/Purpose: Poverty increases non-communicable disease risk, however its influence on systemic lupus erythematosus (SLE) burden is poorly understood. Non-White racial/ethnic groups, particularly of African origin,…
Abstract Number: 0209 • ACR Convergence 2023
Safety of Bivalent SARS-CoV-2 Vaccines as a Second Booster Dose in Arthritis Patients on Immunosuppressive Therapies
Hilde Ørbo¹, Ingrid Jyssum¹, Anne Therese Tveter¹, Ingrid Christensen¹, Joseph Sexton¹, Kristin Hammersbøen Bjørlykke², Grete B. Kro³, Tore Kvien¹, Gunnveig Grødeland⁴, Ludvig A. Munthe⁵, Siri Mjaaland⁶, John Torgils Vaage⁵, Espen Haavardsholm¹, Kristin Kaasen Jørgensen², Sella Provan⁷, Silje Watterdal Syversen¹ and Guro Goll¹, ¹Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ²Department of Gastroenterology, Akershus University Hospital, Oslo, Norway, ³Department of Microbiology, Oslo University Hospital, Oslo, Norway, ⁴Department of Immunology, Oslo University Hospital, Oslo, Norway, ⁵Department of Immunology, Oslo University Hospital, Oslo, Norway, ⁶Norwegian Institute of Public Health, Oslo, Norway, ⁷Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Safety and efficacy of updated bivalent vaccines, containing both the original vaccine variant of SARS-CoV-2 Spike and either Omicron variants BA.1 or BA.4/5, are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].